title: [Clinical Application of Immune-related Response Criteria in Evaluating Chinese Medical Treatme for Advanced Non-small Cell Lung Cancer].
abstract: OBJECTIVE
  To evaluate the applicability of immune-related response criteria (irRC) in treating non-small cell lung cancer (NSCLC) by Chinese medicine (CM).
  
  
  METHODS
  Totally 97 stage III a-IV NSCLC patients were predominantly treated with comprehensive CM. Curative effects were evaluated by three methods such as Response Evaluation Criteria in Solid Tumors (RECIST), Oncologic Curative Effect Evaluation Criteria of Chinese Medicine in Solid Tumor (draft, abbreviated as CM criteria), and irRC. The correspondency and consistency between irRC, RECIST and CM criteria were analyzed and compared. The objectivity of irRC in evaluating curative effect of Chinese medical treatment for NSCLC was assessed.
  
  
  RESULTS
  The correspondency rate of irRC to RECIST was 59. 79% with Kappa value of 0. 379 (U test, P <0. 01). The two criteria had certain correspondence, but with an unsatisfactory consistency. The correspondency rate of irRC to CM criteria rate was 83. 51% with Kappa value of 0.751 (U test, P <0. 01). The two criteria had good correspondence and consistency.
  
  
  CONCLUSIONS
  CM criteria had good consistency with CM criteria in evaluating curative effect for Chinese medical treatment of advanced NSCLC. Its results could objectively reflect features and advantages of CM for treating advanced NSCLC.
authors.forename: Hai-wei
authors.initials: HW
authors.lastname: Jiang
authors.forename: Qing
authors.initials: Q
authors.lastname: Hu
authors.forename: Dan-feng
authors.initials: DF
authors.lastname: He
authors.forename: Chang
authors.initials: C
authors.lastname: Gao
authors.forename: Yan-hong
authors.initials: YH
authors.lastname: Yan
authors.forename: Lin-tong
authors.initials: LT
authors.lastname: Ge
mesh_terms: D044466:Asian People; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000276:immunology*; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000276:immunology*; D008516:Medicine, Chinese Traditional / Q000592:standards*; D016896:Treatment Outcome
chemical_list: D004365:Drugs, Chinese Herbal